• Heron Therapeutics entered a multi-product development and license agreement with Long Grove Pharmaceuticals, with Capstone providing exclusivity covenants.
• Deal grants an exclusive, sublicensable US license to import, distribute, sell, and market certain products covered by licensed patents.
• Heron also received a non-exclusive worldwide manufacturing license for products sold in the US territory.
• Long Grove is eligible for regulatory milestones, sales-based milestones, and royalties; Heron will be reimbursed for certain expenses.
• Agreement runs 10 years from first commercial sale, with automatic two-year renewals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-407728), on September 29, 2026, and is solely responsible for the information contained therein.